Previous 10 | Next 10 |
The following slide deck was published by Dicerna Pharmaceuticals, Inc. in conjunction with this Read more ...
The healthcare sector seems to be waking up over the past several weeks. Political uncertainty has been hurting healthcare stocks throughout the past year, but this uncertainty seems to be dissipating as the Presidential election approaches, which is being a major tailwind for the healthcare ...
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, w...
After a brief lull in pharma industry merger and acquisition activity in recent months, two announcements today have broken the silence. Novartis offered to gobble up The Medicines Compan y (NASDAQ: MDCO) for $9.7 billion in total consideration. Shares of the acquisition target have explo...
Healthcare Pulse Healthcare is at its all-time highs eclipsing the highs recorded a year earlier during the Oct-Nov 2018 period. Of course, if one looks at the broader market which has been recording such all-time highs since the summer of this year, it's understandable to shrug shoulders ...
Hepatitis B virus is responsible for nearly 900,000 deaths each year -- nearly twice as many as malaria -- and is the primary cause of liver cancer, which is the second leading cause of cancer deaths worldwide. That helps explain why investors have been so excited about the latest update from A...
The following slide deck was published by Dicerna Pharmaceuticals, Inc. in conjunction with this Read more ...
Shares of Dicerna Pharmaceuticals (NASDAQ: DRNA) rose over 22% today after the company announced a partnership with Novo Nordisk (NYSE: NVO) . The pair will utilize Dicerna's GalXC technology to develop RNA interference (RNAi) therapies for a wide range of liver-related cardio-metabolic d...
Dicerna Pharmaceuticals (NASDAQ: DRNA ) and Novo Nordisk A/S (NYSE: NVO ) have entered into an agreement to discover and develop novel therapies for the treatment of liver-related cardio-metabolic diseases using Dicerna’s GalXC RNAi platform technology. More news on: Dicerna ...
– Collaboration to Explore Liver Cell Targets Using Dicerna’s GalXC™ Technology With the Potential to Deliver a Significant Number of Clinical Candidates – – Each Company to Retain Rights to Co-Develop and Co-Commercialize Product Candidates – ...
News, Short Squeeze, Breakout and More Instantly...
Dicerna Pharmaceuticals Inc. Company Name:
DRNA Stock Symbol:
NASDAQ Market:
Dicerna Pharmaceuticals Inc. Website:
Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. (Dicerna; Nasdaq: DRNA), announced on 18 November 2021, has been completed. Following the expiration of Novo Nordisk’s cash tender offer for Dicerna, Novo Nordisk has today acquired all outstan...
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Novo Nordisk’s cash tender offer for Dicerna expired at 11:59 p.m., Easter...
Direxion Launches mRNA ETF (MSGR) MSGR Offers Exposure to Rapidly Evolving mRNA Sector PR Newswire NEW YORK , Dec. 9, 2021 /PRNewswire/ -- Direxion announced today the launch of the Direxion mRNA ETF (Ticker: MSGR) . MSGR invests in companies ...